כל המחקרים
גיוסאישור טיפולי (שלב III)התערבותי

A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)

This study is designed for children with early-onset Metachromatic Leukodystrophy (MLD) to confirm the effectiveness and safety of a gene therapy called Libmeldy. MLD is a rare genetic condition that affects the nervous system. The treatment involves using the child's own cells, which are specially modified in the lab, to help produce a missing enzyme. Researchers will primarily be tracking improvements in a child's ability to move and function over a period of 24 months after receiving the gene therapy. They will also be looking at overall health, changes in the brain, how the body responds to the treatment, and any potential side effects. The aim is to understand if this therapy can significantly improve the lives of children with MLD.

במבט חטוף

סטטוס
גיוס
שלב
אישור טיפולי (שלב III)
נותן חסות
Orchard Therapeutics (Europe) Limited
יעד הרשמה
10
התחל
20 במאי 2024

על מה המחקר הזה?

This study is looking at a special type of treatment called gene therapy, known as Libmeldy, for children who have a condition called Metachromatic Leukodystrophy (MLD). MLD is a very rare and serious genetic disease that damages the brain and nervous system, affecting a child's ability to move, talk, and think over time. Currently, there are limited treatments available, so finding effective new options is extremely important.

The gene therapy in this study works by taking some of a child's own blood-forming stem cells, which are then carefully changed in a laboratory. These modified cells are designed to help the child's body produce a missing enzyme called Arylsulfatase A (ARSA). This enzyme is crucial for breaking down certain fats in the body; without it, these fats build up and cause damage to the brain and nerves.

The main goal of this study is to see how well Libmeldy helps children with MLD, especially in terms of their physical movement and overall health, over two years. Researchers will regularly check things like their ability to walk, stand, and balance. They will also monitor how the treatment affects their brain, nerves, and general well-being, while also keeping a very close eye on safety and any side effects. The hope is that this therapy can slow down or stop the progression of MLD and significantly improve the quality of life for these children.

נקודות עיקריות

  • This study is for children with early-onset Metachromatic Leukodystrophy (MLD).
  • It's testing a gene therapy called Libmeldy to see if it helps with movement and health.
  • The treatment involves a single infusion of specially modified cells.
  • Children in the study will be closely monitored for at least two years.
  • The main aim is to confirm the therapy's benefits and ensure its safety.

מי עשוי להיות זכאי?

This study is looking for children of all ages who have early-onset Metachromatic Leukodystrophy (MLD). This means the condition started at a young age.

Both boys and girls can take part in this study. The medical team will review each child's specific health details to make sure this treatment is suitable and safe for them. There might be other specific health requirements that your child needs to meet to be eligible for the study.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Does your child have a confirmed diagnosis of early-onset Metachromatic Leukodystrophy (MLD)?
  2. Is your child within an age range that the medical team believes suitable for the study?
  3. Is your child's overall health stable enough for them to potentially receive this treatment?
  4. Have you discussed your child's full medical history with the study team?
  5. Are you able to commit to regular follow-up appointments over at least two years?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

Taking part in this study would involve several visits to the clinic over a period of at least two years after receiving the gene therapy. You would likely have an initial assessment period to determine if your child is suitable. The treatment itself involves a single infusion of the Libmeldy cells. After the treatment, there will be regular check-ups where doctors will assess your child's movement, nerve function, and overall health. This will involve physical examinations, possibly some scans of the brain (like an MRI), and blood tests. They will also look for any side effects. The total duration of follow-up for some aspects could extend beyond two years to ensure long-term safety and effectiveness.

סיכונים ותועלות פוטנציאליים

Participating in this study might offer your child the chance to receive a cutting-edge gene therapy that could potentially slow down or stop the progression of MLD, improving their movement and overall health. However, like all medical treatments, there are potential risks and side effects, including those from the conditioning treatment needed before the gene therapy, and possible reactions to the infused cells. The study team will monitor your child very closely for any issues. It's important to remember that you have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

מיקומים (1)

חלק מהמיקומים באתר הם משוערים. אנחנו עובדים על שיפור זה — אנא ודאו עם צוות הניסוי לפני הנסיעה.
  • —
    לא מאומת
    איטליה

שאלות נפוצות

What is MLD?

MLD, or Metachromatic Leukodystrophy, is a rare genetic disease that impacts the brain and nervous system, making it difficult for a child to move, speak, and think over time.

What is gene therapy?

Gene therapy is a medical treatment that tries to correct the underlying cause of a disease by changing or replacing faulty genes in the body's cells.

How is Libmeldy given?

Libmeldy is given as a single infusion (like a drip) after your child has received a special preparation called 'conditioning regimen' to prepare their body for the new cells.

כמה זמן יימשך המחקר?

The main part of the study will track your child for at least 24 months (two years) after the treatment, with some assessments possibly continuing for longer to monitor long-term effects.

מה יחפשו החוקרים?

Researchers will be primarily checking how your child's movement and physical abilities change over time. They will also monitor brain health, nerve function, and overall safety.

כיצד לגלות עוד

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A single arm, open label, clinical study of cryopreserved au…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.